To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
18 Nov 2025 - Northern Ireland Troubles Bill - View Vote Context
Adam Jogee (Lab) voted No - in line with the party majority and in line with the House
One of 311 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 165 Noes - 327
Division Vote (Commons)
18 Nov 2025 - Northern Ireland Troubles Bill - View Vote Context
Adam Jogee (Lab) voted Aye - in line with the party majority and in line with the House
One of 310 Labour Aye votes vs 0 Labour No votes
Vote Tally: Ayes - 320 Noes - 105
Speech in Westminster Hall - Mon 17 Nov 2025
Parkinson’s Disease

"I could not have put that better myself.

In Newcastle-under-Lyme, hundreds of local people live with Parkinson’s, and that number is rising. It is a life-altering disease that destroys personal autonomy; it affects someone’s ability to talk, swallow, move and write. Cruel is not the word. For those who are …..."

Adam Jogee - View Speech

View all Adam Jogee (Lab - Newcastle-under-Lyme) contributions to the debate on: Parkinson’s Disease

Speech in Westminster Hall - Mon 17 Nov 2025
Parkinson’s Disease

"I congratulate my hon. Friend the Member for Colne Valley (Paul Davies) on his excellent opening speech. In June this year, my father-in-law, Adrian Lawther, died after living with Parkinson’s for more than a decade. Adrian was a smart, decent and unassuming man, and very much lived the lessons of …..."
Adam Jogee - View Speech

View all Adam Jogee (Lab - Newcastle-under-Lyme) contributions to the debate on: Parkinson’s Disease

Division Vote (Commons)
17 Nov 2025 - Biodiversity Beyond National Jurisdiction Bill - View Vote Context
Adam Jogee (Lab) voted No - in line with the party majority and in line with the House
One of 305 Labour No votes vs 1 Labour Aye votes
Vote Tally: Ayes - 143 Noes - 318
Division Vote (Commons)
17 Nov 2025 - Biodiversity Beyond National Jurisdiction Bill - View Vote Context
Adam Jogee (Lab) voted No - in line with the party majority and in line with the House
One of 304 Labour No votes vs 0 Labour Aye votes
Vote Tally: Ayes - 147 Noes - 318
Written Question
Cancer: Research
Monday 17th November 2025

Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make a comparative assessment of the adequacy of funding for research and innovation for (a) less survivable cancers and (b) other cancer types.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of the largest areas of spend at over £141.6 million in 2024/25, reflecting its high priority.

These investments are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes. An example of this investment is the Imperial College London research on breath tests to detect less survivable cancers, with further information available at the following link:

https://imperialbrc.nihr.ac.uk/2023/06/05/imperial-led-uk-cancer-breath-tests-reach-final-stages/

Another example of Government investment was the launch of the NIHR’s national Brain Tumour Research Consortium in September 2024, which is bringing together researchers from a range of different disciplines and institutions with the aim of making scientific advances in how we prevent, detect, manage, and treat rare and less-survivable brain tumours in adults and children.

The NIHR continues to welcome funding applications for research into less common cancers and other cancer types. The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for less common cancers, and other cancer types.


MP Financial Interest
Adam Jogee (Labour - Newcastle-under-Lyme)
Original Source (17th November 2025)
4. Visits outside the UK
International visit to San Marino between 21 October 2025 and 24 October 2025

Written Question
Oak National Academy
Wednesday 12th November 2025

Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)

Question to the Department for Education:

To ask the Secretary of State for Education, what discussions she has had with publishers on the potential impact of free access overseas to UK-government funded educational resources from Oak National Academy on their exports.

Answered by Georgia Gould - Minister of State (Education)

The department is keeping the geo-restriction of Oak National Academy’s (Oak) resources under review. Oak does not promote or market its resources overseas.

The department recently completed a new market impact assessment (MIA) of Oak, which was published in September 2025, and is available at: https://www.gov.uk/government/publications/oak-national-academy-independent-review-and-market-impact-assessment.


Written Question
Oak National Academy
Wednesday 12th November 2025

Asked by: Adam Jogee (Labour - Newcastle-under-Lyme)

Question to the Department for Education:

To ask the Secretary of State for Education, what plans her Department has to limit access to resources provided by Oak National Academy and funded by the Government through geo-blocking.

Answered by Georgia Gould - Minister of State (Education)

The department is keeping the geo-restriction of Oak National Academy’s (Oak) resources under review. Oak does not promote or market its resources overseas.

The department recently completed a new market impact assessment (MIA) of Oak, which was published in September 2025, and is available at: https://www.gov.uk/government/publications/oak-national-academy-independent-review-and-market-impact-assessment.